News
RENK Group AG (RKGRY) Discusses Pre-Close Update and Strong Order Intake Driven by Defense Contracts Prepared Remarks Transcript
RENK Group AG (RKGRY) Discusses Pre-Close Update and Strong Order Intake Driven by Defense Contracts Prepared Remarks Transcript
Investor AB (publ) (IVSBF) Q2 2026 Earnings Call Transcript
Investor AB (publ) (IVSBF) Q2 2026 Earnings Call Transcript
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion. AtaiBeckley is developing several psychedelics for mental health conditions.
Brazil Potash Provides Update on Autazes Project Regarding Brazilian Court Filing
MANAUS, Brazil, July 16, 2026 (GLOBE NEWSWIRE) -- Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE-American: GRO), a mineral exploration and development company advancing the Autazes potas
Raymond James: Turning Bullish After Earnings Preview And Investor Day (Upgrade)
I raise my rating for Raymond James Financial to a "Buy" after assessing investor event disclosures and previewing its upcoming results release. I expect RJF to beat 3QFY26 EPS consensus, driven by th
AddLife AB (publ) (ADDLF) Q2 2026 Earnings Call Transcript
AddLife AB (publ) (ADDLF) Q2 2026 Earnings Call Transcript
Bunker Hill Mining Strengthens Executive Team and Achieves Improved ESG Rating in Latest Digbee Assessment
KELLOGG, Idaho and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX: BNKR | OTCQB: BHLL) is pleased to announce that Bradle
Alaska Air: The Loss Looks Worse Than The Business
Alaska Air Group is rated Buy with a $60 fair value, reflecting a belief that current losses are driven by temporary fuel shocks. Despite a $193M Q1 loss and suspended guidance, ALK's underlying franc
UnitedHealth Group Profits Hit $5.4 Billion As Costs Continue To Ease
UnitedHealth Group Thursday reported second quarter net income of $5.48 billion as medical costs dropped, triggering an improved financial outlook for the rest of the year.
Richemont: Jewellery Growth Strengthens The Bull Case, But Valuation Has Caught Up (Rating Downgrade)
Compagnie Financière Richemont SA delivered strong Q1 2027 results, led by accelerating Jewellery growth and broad-based sales strength. Jewellery Maisons drove 89% of sales growth, achieving a seven
Traders cool on Tesla-SpaceX merger as Polymarket odds slide
Traders on Polymarket have sharply scaled back bets that a Tesla-SpaceX merger will be announced this year, even as Wall Street analysts insist a tie-up is only a matter of time. The prediction market
Lucid Stock, Down About 44% This Year, Skyrockets Over 28% After CEO Goes on the Offensive Against Bankruptcy Report: 'So Far From the Facts
Lucid Group Inc. (NASDAQ:LCID) CEO Silvio Napoli on Wednesday slammed rumors of the automaker filing for bankruptcy following reports.
Oracle: A Can't-Miss Buy At 52-Week Lows
Oracle has declined over 30% YTD, underperforming peers amid market rotation and debt concerns. I maintain a buy rating, emphasizing Oracle's attractive valuation and resilient core software business
Baron Technology ETF: Technology Dashboard For July
Software appears undervalued by 34% versus historical averages, while other tech sub-sectors are greatly overvalued despite hardware's improved quality score. Baron Technology ETF is an actively manag
Meta: My Concerns Have Finally Alleviated (Rating Upgrade)
I am upgrading Meta Platforms to a buy, driven by its entry into the cloud business and alleviated concerns over excess compute monetization. META's cloud initiative is expected to stabilize cash flow
Phoenix Education Partners: Higher Marketing Spend Has Yet To Repair Growth
I maintain a hold rating on Phoenix Education Partners as student acquisition challenges from AI-powered search now visibly impact financials. PXED reduced FY2026 revenue guidance and raised advertisi
Aker ASA (AKAAF) Q2 2026 Earnings Call Transcript
Aker ASA (AKAAF) Q2 2026 Earnings Call Transcript
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with
Here's how much SpaceX stock crashed below its IPO price
SpaceX (NASDAQ: SPCX) stock fell below its initial public offering (IPO) price of $135 for the first time on Wednesday, July 15.
Dow Inc. Thrives On Growing Gap Between U.S. & Europe Natural Gas Prices
Dow Inc. is rated a buy, with a tactical approach to accumulate shares under $30 and take profits near $40. North American production gives DOW a structural advantage as global natural gas prices rise
